RxDoctor Payments Data

Christopher Kelly, MD

Urology · New York, NYNPI 1366436081

Payments from drug & device makers

$137,502in general payments, 2019–2025

Across 302 payments — averaging $455.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$107K
  • Antares Pharma, Inc.$26K
  • Astellas Pharma US Inc$610
  • Endo USA, Inc.$523
  • Urogen Pharma, Inc.$388
  • Hollister Incorporated$308
  • plus $2K from 16 others

What the payments were for

  • Consulting fees$95,25069%
  • Speaking & faculty fees$24,75018%
  • Travel & lodging$4,2653%
  • Food & beverage$11,7059%
  • Education$3650%
  • Gifts$1,1671%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Procept Biorobotics Corporation131$107,409
Antares Pharma, Inc.33$26,368
Astellas Pharma US Inc19$610
Endo USA, Inc.31$523
Urogen Pharma, Inc.15$388
Hollister Incorporated12$308
Endo Pharmaceuticals Inc.16$292
ABC Home Medical Supply, Inc.7$247
Olympus America Inc.2$240
Dentsply IH AB10$182
AbbVie(2 entities)7$167
Dentsply IH Inc.5$143
Boston Scientific2$139
Axonics, Inc.1$127
Teleflex LLC2$112
180 Medical, Inc.2$108
Coloplast2$42
Civco Medical Instruments1$26
Millicent US Inc1$20
Bard Peripheral Vascular, Inc.1$19
Novo Nordisk1$16
Clarus Therapeutics Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,502 in reported general payments places this provider in the 90th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$542,707
Medicare patients
1,630
Services billed
11,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron553$380,058
GemtesaVibegron350$298,244
XyostedTestosterone Enanthate120$90,404
Tadalafil672$54,061
Silodosin641$45,901
Mirabegron ErMirabegron49$30,095
Finasteride1,312$20,338
Alfuzosin Hcl ErAlfuzosin Hcl807$16,572
Tamsulosin Hcl917$14,497
Dutasteride256$9,953
Testosterone42$9,009
Methenamine Hippurate83$6,013
Solifenacin Succinate91$5,748
Fosfomycin Tromethamine21$5,159
Trospium Chloride ErTrospium Chloride13$3,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$610$380,058553 claims
Antares Pharma, Inc.Xyosted$26,368$90,404120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 952 urology providers in New York.

Other urology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →